Clinical Trial

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Name: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL — clinical trial record (NCT06880913)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Phase I/II

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-03-16.

Trial Details

NCT Number	NCT06880913
Lead Sponsor	Peking University People's Hospital Collaborators: Hebei Senlang Biotechnology Inc., Ltd.
Conditions	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Enrollment	50 participants
Start Date	2024-11-14
Primary Completion	2026-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-30